|ESMO consensus guidelines for the management of patients with metastatic colorectal cancer|
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
|Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a …|
PM Hoff, R Ansari, G Batist, J Cox, W Kocha, M Kuperminc, J Maroun, ...
Journal of Clinical Oncology 19 (8), 2282-2292, 2001
|ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making|
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
|Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases|
N Vauthey, T Pawlik, D Ribero, TT Wu, D Zorzi, P Hoff, H Xiong, C Eng, ...
|Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas|
MA Kouvaraki, JA Ajani, P Hoff, R Wolff, DB Evans, R Lozano, JC Yao
Journal of Clinical Oncology 22 (23), 4762-4771, 2004
|First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin|
J Cassidy, C Twelves, E Van Cutsem, P Hoff, E Bajetta, M Boyer, R Bugat, ...
Annals of oncology 13 (4), 566-575, 2002
|Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines|
AD Yang, F Fan, ER Camp, G van Buren, W Liu, R Somcio, MJ Gray, ...
Clinical cancer research 12 (14), 4147-4153, 2006
|Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial|
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
|Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study|
LB Saltz, HJ Lenz, HL Kindler, HS Hochster, S Wadler, PM Hoff, ...
Journal of Clinical Oncology 25 (29), 4557-4561, 2007
|Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials|
E Van Cutsem, PM Hoff, P Harper, RM Bukowski, D Cunningham, ...
British journal of cancer 90 (6), 1190-1197, 2004
|Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …|
S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ...
Journal of clinical oncology 28 (3), 453, 2010
|Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b|
JC Yao, A Phan, PM Hoff, HX Chen, C Charnsangavej, SCJ Yeung, ...
Journal of Clinical Oncology 26 (8), 1316-1323, 2008
|Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer|
JY Douillard, PM Hoff, JR Skillings, P Eisenberg, N Davidson, P Harper, ...
Journal of Clinical Oncology 20 (17), 3605-3616, 2002
|Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal …|
JR Hecht, YJ Bang, SK Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 34 (5), 443-451, 2016
|Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer|
NA Janjan, C Crane, BW Feig, K Cleary, R Dubrow, S Curley, JN Vauthey, ...
American journal of clinical oncology 24 (2), 107-112, 2001
|Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics|
L Claret, P Girard, PM Hoff, E Van Cutsem, KP Zuideveld, K Jorga, ...
Journal of Clinical Oncology 27 (25), 4103-4108, 2009
|Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer|
LB Saltz, HJ Lenz, H Hochster, S Wadler, P Hoff, N Kemeny, E Hollywood, ...
Journal of Clinical Oncology 23 (16_suppl), 3508-3508, 2005
|Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients|
M Bonnen, C Crane, JN Vauthey, J Skibber, ME Delclos, ...
International Journal of Radiation Oncology* Biology* Physics 60 (4), 1098-1105, 2004
|Potential regional differences for the tolerability profiles of fluoropyrimidines|
DG Haller, J Cassidy, SJ Clarke, D Cunningham, E Van Cutsem, PM Hoff, ...
Journal of Clinical Oncology 26 (13), 2118-2123, 2008
|Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial|
MS Avila, SM Ayub-Ferreira, MR de Barros Wanderley, F das Dores Cruz, ...
Journal of the American College of Cardiology 71 (20), 2281-2290, 2018